Melatonin combined with sorafenib synergistically inhibit the invasive ability through targeting metastasis-associated protein 2 expression in human renal cancer cells

Melatonin combined with sorafenib synergistically inhibit the invasive ability through targeting metastasis-associated protein 2 expression in human renal cancer cells

Objectives: Renal cell carcinoma (RCC) was the most common and lethal urological malignancy with the dismal outcome when distant metastasis. Melatonin was known as a potential oncostatic agent against several types of malignancy and sorafenib had been considered as an agent to treat RCC, but the syn...

Full description

Bibliographic Details
Main Authors: Chu-Che Lee, Po-Yu Huang, Yi-Hsien Hsieh, Yong-Syuan Chen, Jen-Pi Tsai
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:Tzu-Chi Medical Journal
Subjects:
melatonin
metastasis-associated protein 2
renal cell carcinoma
sorafenib
Online Access:http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2022;volume=34;issue=2;spage=192;epage=199;aulast=Lee

Internet

http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2022;volume=34;issue=2;spage=192;epage=199;aulast=Lee

Similar Items